KROS- Keros Therapeutics, Inc.
Keros Therapeutics, Inc. (KROS) has 8 insiders with recent SEC Form 4 filings, including 28 buys and 0 sells. KROS is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 759.2K | $8.08M | - | |
| Dir | 759.2K | $8.08M | - | |
| Dir | 102.2K | $1.09M | - | |
| CEO | 62.5K | $665.0K | - | |
| Dir | 17.6K | $187.2K | - |
Activity
Buys and sells only
Transactions
10 filings · page 6
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2020 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Buy | 60,000 | $50.00 | $3,000,000.00 | +1.3% | |
| Nov 17, 2020 | Nussbaum Ran | Director, 10% Owner | Buy | 60,000 | $50.00 | $3,000,000.00 | +1.3% | |
| Nov 17, 2020 | Kariv Tomer | Director, 10% Owner | Buy | 60,000 | $50.00 | $3,000,000.00 | +1.3% | |
| Apr 13, 2020 | Kariv Tomer | Director, 10% Owner | Buy | 437,499 | $16.00 | $6,999,984.00 | +10.2% | |
| Apr 13, 2020 | Knowles Julius62 | Director | Buy | 1,191 | $20.98 | $24,987.18 | New | |
| Apr 13, 2020 | Seehra Jasbir | Chief Executive Officer | Buy | 20,000 | $16.00 | $320,000.00 | +8.9% | |
| Apr 13, 2020 | Orbimed Advisors LLC66 | Director | Buy | 375,200 | $16.00 | $6,003,200.00 | +50.4% | |
| Apr 13, 2020 | Lazarus Alon | Director, 10% Owner | Buy | 120,000 | $16.00 | $1,920,000.00 | +6.3% | |
| Apr 13, 2020 | Nussbaum Ran | Director, 10% Owner | Buy | 437,499 | $16.00 | $6,999,984.00 | +10.2% | |
| Apr 13, 2020 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Buy | 437,499 | $16.00 | $6,999,984.00 | +10.2% |